A Phase 3 interventional study of 5-grass mix SLIT-drops and Placebo in Allergy, sponsored by ALK-Abelló A/S. Completed at 48 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-16.
Sponsored by ALK-Abelló A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Hypersensitivity by ALK-Abelló A/S — none open to participants now, none under way, none of them phase 3. Hypersensitivity · ALK-Abelló A/S.
Among the 30 studies in Hypersensitivity by ALK-Abelló A/S, this one is the 6th largest by enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2021, is one of 13 in phase 3, and was the 28th registered.
1,058 studies on the registry are indexed under Hypersensitivity; 152 are open to participants now.
Browse Hypersensitivity studies →None of the 30 studies in Hypersensitivity by ALK-Abelló A/S is open now. The open studies under Hypersensitivity, anywhere →
Of the 101 Hypersensitivity studies recruiting now, 37 (37%) set no upper age limit and 52 (51%) stop at 75 or younger; 56 take children under 18; 37 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 8 · Phase 3 16 · Phase 4 1
First in 2004; this study’s year is marked. 2 started in 2021.
This study's enrollment of 445 is above the median of 73 across 692 interventional studies indexed under Hypersensitivity.
Median enrollment 226 across the 25 interventional studies, 24,481 across the 4 observational. Of the 29 that completed or were terminated, 9 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
ALK-Abelló A/S is the lead sponsor of 67 studies on the registry; 2 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 30 studies in Hypersensitivity by ALK-Abelló A/S, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a 2 year clinical study to compare 5-grass mix SLIT-drops with placebo in relieving grass pollen-induced rhinoconjunctivitis symptoms and in use of symptom-relieving medication during the second grass pollen season (peak grass pollen season, PGPS)
The study will collect health-related quality of life data in the groups treated with 5-grass mix SLIT-drops or with placebo during the first and second PGPS.
The trial medication used is already approved to treat allergic rhinitis caused by grass pollen in adults in several countries.
This trial is a 2 year, parallel-group, double-blind, placebo-controlled phase III trial to evaluate efficacy and safety of the 5-grass mix SLIT-drops in adults with grass pollen-induced rhinoconjunctivitis with or without asthma. Approximately 440 adults will be enrolled in the trial and will receive the 5-grass mix SLIT-drops or placebo. The trial is conducted in several European countries.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Glycerol, carbonate, sodium chloride One single-dose container (0.5 ml) once daily
Drug: Placebo
Grass mix sublingual allergy immunotherapy drops One single-dose container (0.5 ml) once daily. 50 SRU/day for five consecutive days followed by 150 SRU/day for five additional consecutive days. Maintenance: 300 SRU/day from day 11.
Drug: 5-grass mix SLIT-drops
Sublingual allergy immunotherapy drops, for daily administration
Also known as: SLIToneULTRA
Placebo
Average Daily Allergic Rhinoconjunctivitis Total Combined Score (TCS) During the 2nd Peak Grass Pollen Season (PGPS)
The average daily TCS evaluates the treatment effect based on reduction in daily rhinoconjunctivitis symptoms and in use of symptom-relieving medication (on a scale from 0 to 38). Higher scores indicate more severe symptoms and/or more medication use. The endpoint is calculated as the average score of all reported daily values during the 2nd PGPS.
Time frame: During the 2nd PGPS (14 days)
Average Weekly Overall Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) Score During the 2nd Peak Grass Pollen Season (PGPS)
The RQLQ measures the rhinoconjunctivitis quality of life. The RQLQ contains 28 questions, each scored on a 7-point scale (0 = not impaired at all; 6 = severely impaired). The overall RQLQ score is a mean of the 28 questions. Higher scores indicate worse quality of life. The endpoint is calculated as the average score of all reported weekly values during the 2nd PGPS.
Time frame: During the 2nd PGPS (14 days)
Average Daily Allergic Rhinoconjunctivitis Total Combined Score (TCS) During the 1st Peak Grass Pollen Season (PGPS)
The average daily TCS evaluates the treatment effect based on reduction in daily rhinoconjunctivitis symptoms and in use of symptom-relieving medication (on a scale from 0 to 38). Higher scores indicate more severe symptoms and/or more medication use. The endpoint is calculated as the average score of all reported daily values during the 1st PGPS.
Time frame: During the 1st PGPS (14 days)
Average Weekly Overall Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) Score During the 1st Peak Grass Pollen Season (PGPS)
The RQLQ measures the rhinoconjunctivitis quality of life. The RQLQ contains 28 questions, each scored on a 7-point scale (0 = not impaired at all; 6 = severely impaired). The overall RQLQ score is a mean of the 28 questions. Higher scores indicate worse quality of life. The endpoint is calculated as the average score of all reported weekly values during the 1st PGPS.
Time frame: During the 1st PGPS (14 days)
Average Weekly Overall Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) Score During the 1st Entire Grass Pollen Season (EGPS)
The RQLQ measures the rhinoconjunctivitis quality of life. The RQLQ contains 28 questions, each scored on a 7-point scale (0 = not impaired at all; 6 = severely impaired). The overall RQLQ score is a mean of the 28 questions. Higher scores indicate worse quality of life. The endpoint is calculated as the average score of all reported weekly values during the 1st EGPS.
Time frame: During the 1st EGPS (observed mean duration of approximately 8 weeks)
Average Weekly Overall Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) Score During the 2nd Entire Grass Pollen Season (EGPS)
The RQLQ measures the rhinoconjunctivitis quality of life. The RQLQ contains 28 questions, each scored on a 7-point scale (0 = not impaired at all; 6 = severely impaired). The overall RQLQ score is a mean of the 28 questions. Higher scores indicate worse quality of life. The endpoint is calculated as the average score of all reported weekly values during the 2nd EGPS.
Time frame: During the 2nd EGPS (observed mean duration of approximately 9 weeks)
Average Daily Allergic Rhinoconjunctivitis Total Combined Score (TCS) During the 1st Entire Grass Pollen Season (EGPS)
The average daily TCS evaluates the treatment effect based on reduction in daily rhinoconjunctivitis symptoms and in use of symptom-relieving medication (on a scale from 0 to 38). Higher scores indicate more severe symptoms and/or more medication use. The endpoint is calculated as the average score of all reported daily values during the 1st EGPS.
Time frame: During the 1st EGPS (observed mean duration of approximately 8 weeks)
Average Daily Allergic Rhinoconjunctivitis Total Combined Score (TCS) During the 2nd Entire Grass Pollen Season (EGPS)
The average daily TCS evaluates the treatment effect based on reduction in daily rhinoconjunctivitis symptoms and in use of symptom-relieving medication (on a scale from 0 to 38). Higher scores indicate more severe symptoms and/or more medication use. The endpoint is calculated as the average score of all reported daily values during the 2nd EGPS.
Time frame: During the 2nd EGPS (observed mean duration of approximately 9 weeks)
Average Allergic Rhinoconjunctivitis Daily Symptoms Score (DSS) During the 1st Peak Grass Pollen Season (PGPS)
The average DSS evaluates the treatment effect based on reduction in daily rhinoconjunctivitis symptoms (on a scale from 0 to18). Higher scores indicate more severe symptoms. The endpoint is calculated as the average score of all reported daily values during the 1st PGPS.
Time frame: During the 1st PGPS (14 days)
Average Allergic Rhinoconjunctivitis Daily Symptoms Score (DSS) During the 2nd Peak Grass Pollen Season (PGPS)
The average DSS evaluates the treatment effect based on reduction in daily rhinoconjunctivitis symptoms (on a scale from 0 to18). Higher scores indicate more severe symptoms. The endpoint is calculated as the average score of all reported daily values during the 2nd PGPS.
Time frame: During the 2nd PGPS (14 days)
Average Allergic Rhinoconjunctivitis Daily Symptoms Score (DSS) During the 1st Entire Grass Pollen Season (EGPS)
The average DSS evaluates the treatment effect based on reduction in daily rhinoconjunctivitis symptoms (on a scale from 0 to18). Higher scores indicate more severe symptoms. The endpoint is calculated as the average score of all reported daily values during the 1st EGPS.
Time frame: During the 1st EGPS (observed mean duration of approximately 8 weeks)
Average Allergic Rhinoconjunctivitis Daily Symptoms Score (DSS) During the 2nd Entire Grass Pollen Season (EGPS)
The average DSS evaluates the treatment effect based on reduction in daily rhinoconjunctivitis symptoms (on a scale from 0 to18). Higher scores indicate more severe symptoms. The endpoint is calculated as the average score of all reported daily values during the 2nd EGPS.
Time frame: During the 2nd EGPS (observed mean duration of approximately 9 weeks)
Average Allergic Rhinoconjunctivitis Daily Medication Score (DMS) During the 1st Peak Grass Pollen Season (PGPS)
The average DMS evaluates the treatment effect based on reduction in daily use of rhinoconjunctivitis symptom-relieving medication (on a scale from 0 to 20). Higher scores indicate more medication use. The endpoint is calculated as the average score of all reported daily values during the 1st PGPS.
Time frame: During the 1st PGPS (14 days)
Average Allergic Rhinoconjunctivitis Daily Medication Score (DMS) During the 2nd Peak Grass Pollen Season (PGPS)
The average DMS evaluates the treatment effect based on reduction in daily use of rhinoconjunctivitis symptom-relieving medication (on a scale of 0 to 20). Higher scores indicate more medication use. The endpoint is calculated as the average score of all reported daily values during the 2nd PGPS.
Time frame: During the 2nd PGPS (14 days)
Average Allergic Rhinoconjunctivitis Daily Medication Score (DMS) During the 1st Entire Grass Pollen Season (EGPS)
The average DMS evaluates the treatment effect based on reduction in daily use of rhinoconjunctivitis symptom-relieving medication(on a scale from 0 to 20). Higher scores indicate more medication use. The endpoint is calculated as the average score of all reported daily values during the 1st EGPS.
Time frame: During the 1st EGPS (observed mean duration of approximately 8 weeks)
Average Allergic Rhinoconjunctivitis Daily Medication Score (DMS) During the 2nd Entire Grass Pollen Season (EGPS)
The average DMS evaluates the treatment effect based on reduction in daily use of rhinoconjunctivitis symptom-relieving medication (on a scale from 0 to 20). Higher scores indicate more medication use. The endpoint is calculated as the average score of all reported daily values during the 2nd EGPS.
Time frame: During the 2nd EGPS (observed mean duration of approximately 9 weeks)
445 participants were randomized and treated. Participants were recruited from 45 sites in 6 countries (Czechia, Estonia, France, Latvia, Lithuania, and Poland).
| Milestone | Placebo | 5-grass Mix SLIT-drops |
|---|---|---|
| Started | 223 | 222 |
| Completed | 196 | 193 |
| Not completed | 27 | 29 |
| Withdrew: Adverse event | 2 | 4 |
| Withdrew: Withdrawal by subject | 19 | 19 |
| Withdrew: Lost to follow-up | 4 | 4 |
| Withdrew: Lack of efficacy | 1 | 0 |
| Withdrew: Reason stated as "other" in crf | 1 | 2 |
The average daily TCS evaluates the treatment effect based on reduction in daily rhinoconjunctivitis symptoms and in use of symptom-relieving medication (on a scale from 0 to 38). Higher scores indicate more severe symptoms and/or more medication use. The endpoint is calculated as the average score of all reported daily values during the 2nd PGPS.
| score on a scale | Placebo | 5-grass Mix SLIT-drops |
|---|---|---|
| Average Daily Allergic Rhinoconjunctivitis Total Combined Score (TCS) During the 2nd Peak Grass Pollen Season (PGPS) | 7.10 ± 0.51 | 5.22 ± 0.42 |
The RQLQ measures the rhinoconjunctivitis quality of life. The RQLQ contains 28 questions, each scored on a 7-point scale (0 = not impaired at all; 6 = severely impaired). The overall RQLQ score is a mean of the 28 questions. Higher scores indicate worse quality of life. The endpoint is calculated as the average score of all reported weekly values during the 2nd PGPS.
| score on a scale | Placebo | 5-grass Mix SLIT-drops |
|---|---|---|
| Average Weekly Overall Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) Score During the 2nd Peak Grass Pollen Season (PGPS) | 1.04 ± 0.08 | 0.86 ± 0.08 |
The average daily TCS evaluates the treatment effect based on reduction in daily rhinoconjunctivitis symptoms and in use of symptom-relieving medication (on a scale from 0 to 38). Higher scores indicate more severe symptoms and/or more medication use. The endpoint is calculated as the average score of all reported daily values during the 1st PGPS.
| score on a scale | Placebo | 5-grass Mix SLIT-drops |
|---|---|---|
| Average Daily Allergic Rhinoconjunctivitis Total Combined Score (TCS) During the 1st Peak Grass Pollen Season (PGPS) | 8.10 ± 0.54 | 6.76 ± 0.42 |
The RQLQ measures the rhinoconjunctivitis quality of life. The RQLQ contains 28 questions, each scored on a 7-point scale (0 = not impaired at all; 6 = severely impaired). The overall RQLQ score is a mean of the 28 questions. Higher scores indicate worse quality of life. The endpoint is calculated as the average score of all reported weekly values during the 1st PGPS.
| score on a scale | Placebo | 5-grass Mix SLIT-drops |
|---|---|---|
| Average Weekly Overall Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) Score During the 1st Peak Grass Pollen Season (PGPS) | 1.26 ± 0.09 | 1.19 ± 0.08 |
The RQLQ measures the rhinoconjunctivitis quality of life. The RQLQ contains 28 questions, each scored on a 7-point scale (0 = not impaired at all; 6 = severely impaired). The overall RQLQ score is a mean of the 28 questions. Higher scores indicate worse quality of life. The endpoint is calculated as the average score of all reported weekly values during the 1st EGPS.
| score on a scale | Placebo | 5-grass Mix SLIT-drops |
|---|---|---|
| Average Weekly Overall Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) Score During the 1st Entire Grass Pollen Season (EGPS) | 1.16 ± 0.09 | 1.09 ± 0.08 |
The RQLQ measures the rhinoconjunctivitis quality of life. The RQLQ contains 28 questions, each scored on a 7-point scale (0 = not impaired at all; 6 = severely impaired). The overall RQLQ score is a mean of the 28 questions. Higher scores indicate worse quality of life. The endpoint is calculated as the average score of all reported weekly values during the 2nd EGPS.
| score on a scale | Placebo | 5-grass Mix SLIT-drops |
|---|---|---|
| Average Weekly Overall Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) Score During the 2nd Entire Grass Pollen Season (EGPS) | 1.03 ± 0.08 | 0.83 ± 0.07 |
The average daily TCS evaluates the treatment effect based on reduction in daily rhinoconjunctivitis symptoms and in use of symptom-relieving medication (on a scale from 0 to 38). Higher scores indicate more severe symptoms and/or more medication use. The endpoint is calculated as the average score of all reported daily values during the 1st EGPS.
| score on a scale | Placebo | 5-grass Mix SLIT-drops |
|---|---|---|
| Average Daily Allergic Rhinoconjunctivitis Total Combined Score (TCS) During the 1st Entire Grass Pollen Season (EGPS) | 7.42 ± 0.54 | 6.23 ± 0.45 |
The average daily TCS evaluates the treatment effect based on reduction in daily rhinoconjunctivitis symptoms and in use of symptom-relieving medication (on a scale from 0 to 38). Higher scores indicate more severe symptoms and/or more medication use. The endpoint is calculated as the average score of all reported daily values during the 2nd EGPS.
| score on a scale | Placebo | 5-grass Mix SLIT-drops |
|---|---|---|
| Average Daily Allergic Rhinoconjunctivitis Total Combined Score (TCS) During the 2nd Entire Grass Pollen Season (EGPS) | 6.58 ± 0.50 | 4.86 ± 0.43 |
The average DSS evaluates the treatment effect based on reduction in daily rhinoconjunctivitis symptoms (on a scale from 0 to18). Higher scores indicate more severe symptoms. The endpoint is calculated as the average score of all reported daily values during the 1st PGPS.
| score on a scale | Placebo | 5-grass Mix SLIT-drops |
|---|---|---|
| Average Allergic Rhinoconjunctivitis Daily Symptoms Score (DSS) During the 1st Peak Grass Pollen Season (PGPS) | 4.08 ± 0.27 | 3.83 ± 0.23 |
The average DSS evaluates the treatment effect based on reduction in daily rhinoconjunctivitis symptoms (on a scale from 0 to18). Higher scores indicate more severe symptoms. The endpoint is calculated as the average score of all reported daily values during the 2nd PGPS.
| score on a scale | Placebo | 5-grass Mix SLIT-drops |
|---|---|---|
| Average Allergic Rhinoconjunctivitis Daily Symptoms Score (DSS) During the 2nd Peak Grass Pollen Season (PGPS) | 3.64 ± 0.26 | 3.09 ± 0.25 |
The average DSS evaluates the treatment effect based on reduction in daily rhinoconjunctivitis symptoms (on a scale from 0 to18). Higher scores indicate more severe symptoms. The endpoint is calculated as the average score of all reported daily values during the 1st EGPS.
| score on a scale | Placebo | 5-grass Mix SLIT-drops |
|---|---|---|
| Average Allergic Rhinoconjunctivitis Daily Symptoms Score (DSS) During the 1st Entire Grass Pollen Season (EGPS) | 3.82 ± 0.24 | 3.61 ± 0.22 |
The average DSS evaluates the treatment effect based on reduction in daily rhinoconjunctivitis symptoms (on a scale from 0 to18). Higher scores indicate more severe symptoms. The endpoint is calculated as the average score of all reported daily values during the 2nd EGPS.
| score on a scale | Placebo | 5-grass Mix SLIT-drops |
|---|---|---|
| Average Allergic Rhinoconjunctivitis Daily Symptoms Score (DSS) During the 2nd Entire Grass Pollen Season (EGPS) | 3.46 ± 0.23 | 2.89 ± 0.22 |
The average DMS evaluates the treatment effect based on reduction in daily use of rhinoconjunctivitis symptom-relieving medication (on a scale from 0 to 20). Higher scores indicate more medication use. The endpoint is calculated as the average score of all reported daily values during the 1st PGPS.
| units on a scale | Placebo | 5-grass Mix SLIT-drops |
|---|---|---|
| Average Allergic Rhinoconjunctivitis Daily Medication Score (DMS) During the 1st Peak Grass Pollen Season (PGPS) | 3.34 ± 0.34 | 2.23 ± 0.25 |
The average DMS evaluates the treatment effect based on reduction in daily use of rhinoconjunctivitis symptom-relieving medication (on a scale of 0 to 20). Higher scores indicate more medication use. The endpoint is calculated as the average score of all reported daily values during the 2nd PGPS.
| score on a scale | Placebo | 5-grass Mix SLIT-drops |
|---|---|---|
| Average Allergic Rhinoconjunctivitis Daily Medication Score (DMS) During the 2nd Peak Grass Pollen Season (PGPS) | 2.77 ± 0.30 | 1.52 ± 0.21 |
The average DMS evaluates the treatment effect based on reduction in daily use of rhinoconjunctivitis symptom-relieving medication(on a scale from 0 to 20). Higher scores indicate more medication use. The endpoint is calculated as the average score of all reported daily values during the 1st EGPS.
| score on a scale | Placebo | 5-grass Mix SLIT-drops |
|---|---|---|
| Average Allergic Rhinoconjunctivitis Daily Medication Score (DMS) During the 1st Entire Grass Pollen Season (EGPS) | 3.04 ± 0.35 | 2.10 ± 0.27 |
The average DMS evaluates the treatment effect based on reduction in daily use of rhinoconjunctivitis symptom-relieving medication (on a scale from 0 to 20). Higher scores indicate more medication use. The endpoint is calculated as the average score of all reported daily values during the 2nd EGPS.
| score on a scale | Placebo | 5-grass Mix SLIT-drops |
|---|---|---|
| Average Allergic Rhinoconjunctivitis Daily Medication Score (DMS) During the 2nd Entire Grass Pollen Season (EGPS) | 2.62 ± 0.31 | 1.51 ± 0.23 |
Collected over Adverse events (AEs) were collected from consent until the last follow-up phone contact with the participant (approximately 26 months of treatment). The displayed AEs were collected starting on/after time of first IMP administration and no later than 7 days after last IMP administration.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/223 (0%) | 6/223 (2.7%) | 111/223 (49.8%) |
| 5-grass Mix SLIT-drops | 0/222 (0%) | 4/222 (1.8%) | 128/222 (57.7%) |
| Event | Placebo | 5-grass Mix SLIT-drops |
|---|---|---|
| CholelithiasisHepatobiliary disorders | 1/223 | 1/222 |
| AppendicitisInfections and infestations | 0/223 | 1/222 |
| Gastrointestinal procedural complicationInjury, poisoning and procedural complications | 0/223 | 1/222 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/223 | 1/222 |
| Ovarian cyst rupturedReproductive system and breast disorders | 0/223 | 1/222 |
| ChokingRespiratory, thoracic and mediastinal disorders | 0/223 | 1/222 |
| DiverticulitisInfections and infestations | 1/223 | 0/222 |
| Lumbar vertebral fractureInjury, poisoning and procedural complications | 1/223 | 0/222 |
| Wrist fractureInjury, poisoning and procedural complications | 1/223 | 0/222 |
| Device breakageProduct Issues | 1/223 | 0/222 |
| Event | Placebo | 5-grass Mix SLIT-drops |
|---|---|---|
| COVID-19Infections and infestations | 43/223 | 41/222 |
| NasopharyngitisInfections and infestations | 43/223 | 38/222 |
| Oral pruritusGastrointestinal disorders | 11/223 | 40/222 |
| PharyngitisInfections and infestations | 20/223 | 4/222 |
| HeadacheNervous system disorders | 19/223 | 11/222 |
| Throat irritationRespiratory, thoracic and mediastinal disorders | 4/223 | 16/222 |
| Oral discomfortGastrointestinal disorders | 1/223 | 15/222 |
| Upper respiratory tract infectionInfections and infestations | 15/223 | 10/222 |
| Viral infectionInfections and infestations | 7/223 | 14/222 |
| BronchitisInfections and infestations | 14/223 | 7/222 |
All randomized and treated participants
| Age, Continuous(Years) | Placebo | 5-grass Mix SLIT-drops | Total |
|---|---|---|---|
| Mean | 33.0 ± 9.7 | 32.2 ± 10.1 | 32.6 ± 9.9 |
| Sex: Female, Male(Participants) | Placebo | 5-grass Mix SLIT-drops | Total |
|---|---|---|---|
| Female | 105 | 95 | 200 |
| Male | 118 | 127 | 245 |
| Race/Ethnicity, Customized(Participants) | Placebo | 5-grass Mix SLIT-drops | Total |
|---|---|---|---|
| White | 223 | 222 | 445 |
| Region of Enrollment(participants) | Placebo | 5-grass Mix SLIT-drops | Total |
|---|---|---|---|
| Czechia | 56 | 57 | 113 |
| Estonia | 2 | 0 | 2 |
| France | 6 | 7 | 13 |
| Latvia | 17 | 16 | 33 |
| Lithuania | 25 | 26 | 51 |
| Poland | 117 | 116 | 233 |
| Ongoing asthma(Participants) | Placebo | 5-grass Mix SLIT-drops | Total |
|---|---|---|---|
| Count of participants | 63 | 59 | 122 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2021 to primary completion in Sep 2023, 28 months.
Results were first posted in Dec 2024, 1 year 2 months after primary completion.
Of 32 industry-sponsored phase 3 interventional studies under Hypersensitivity, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 34. This study's 28 months is above that.
Counting every sponsor, half of 42 studies reached it within 23 months; a quarter within 10 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.